C-OAXVgenetic medicines, non-viral delivery, senescent cell removal
Editor’s Choice. Hand-picked by the Eternal Search editors as worth your attention — a curatorial call shown alongside, not instead of, the computed score.
0-100 chain-logic scale · 15 dimensions · scored on public evidence
LongX presents our Fireside Chat with Matthew Scholz: Biotech Visionary, Serial Entrepreneur, and CEO of Oisín Biotechnologies. Matthew Scholz is the founder of multiple pioneering companies in the biotech space, including Immusoft and Oisín Biotechnologies. With a background in both computer science and immunology, Matthew has spent the past decade building platforms that reprogram the human body to treat aging and disease. Immusoft, his first biotech company, developed a way to engineer B cells to act as “living drug factories,” enabling long-term protein production within the patient’s own immune system. Under Matthew’s leadership, Immusoft became the first company to bring engineered B cell therapy into human trials. After Immusoft, Matthew co-founded Oisín Biotechnologies, where he now serves as CEO. Oisín is focused on clearing senescent cells that contribute to aging and chronic disease using DNA-targeted interventions. He also co-founded OncoSenX, a spinout developing target
Matthew Scholz Founder and CEO, Oisín Biotechnologies Oisin is developing therapeutics that kill cells based on gene activity. It currently has assets targeting senescent cells for age-related pathologies and cancerous cells for solid tumors. https://www.oisinbio.com/ https://www.linkedin.com/in/matthewscholz/ Cognitum: https://www.youtube.com/@CognitumTV https://www.linkedin.com/in/iosifmg/ https://x.com/IMGpf Cognitum extends a special thanks the organizers of the 2024 Biomarkers of Aging Conference © 2024
Oisín Biotechnologies, Presented By Matthew Scholz, PhD, CEO - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Gene Therapy for Longevity: Oisín Biotechnologies Thu May 6, 2021 Q&A with Matthew Scholz, co-founder and CEO of Oisín Bio (oisinbio.com).
Jay Richards interviews Matt Scholz, Founder & CEO of Oisín Biotechnologies about the challenges and promises of the information theory of biotech. Besides the regulatory environment, Scholz believes that one of the biggest impediments to breakthroughs in medicine is the ability to empower the patient. Strangely, the one person who has no say in healthcare is the patient who ought to be "the arbiter of what goes into their body and not just be subject to the whims of the system." Matthew Scholz is Immusoft’s founder and served as the company’s Chief Executive Officer from 2009 through 2017. Immusoft’s inflection point as a company came when Matthew conceived how a research system developed by Nobel Laureate and former President of Caltech, David Baltimore, could be modified for a practical application: programming resting B cells to secrete therapeutic proteins. He negotiated an exclusive license to the system, then developed and patented a way to improve its efficiency to the point
Zoom Transcription: https://otter.ai/s/xosV12EvQa2k9ZO-eDJpYw 1. Self-Sovereign Identity for Health Commons As a follow-up to our health commons meeting, Adrian Gropper, Trustee, will give an intro to how self-sovereign identity could aid with concerns around privacy and data analysis. Trustee uses self-sovereign identity to enable experts such as a credentialed physician or a defense attorney to interact directly with a self-sovereign person, who can avoid correlation by platforms, service providers, and other powerful surveillance entities. 2. Senolytic Drugs as COVID-19 Response Matthew Scholz, Oisin Biotech, will give an intro on how senolytic technology could potentially function as COVID-19 response/prophylaxis. Oisin targets the clearance of senescent cells using drugs known as senolytics, with technology that can be programmed to kill any type of cell by targeting a specific protein that it expresses; typically, this would be p16 for senescent cells. Background on
Oisin Biotechnologies | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Oisin Biotechnologies Oisín Biotechnologies is focused on developing genetic medicines for health and longevity. They have a robust pipeline targeting multiple drivers of age-related conditions, including programs that stimulate muscle growth, selectively kill fat cells, and remove senescent cells. Their therapies leverage a new, non-viral delivery technology called Fusogenix™ Proteo-Lipid Vehicle (PLV), which enables extensive biodistribution for DNA and
Oisín Biotechnologies - Pioneering Genetic Medicines for Sarcopenia | VitaDAO WHY LONGEVITY RESEARCH VITA LABS VITA TOKEN PROJECTS BLOG STORE GET VITA LOADING EQUITY A VITADAO PROJECT Oisín Biotechnologies - Pioneering Genetic Medicines for Sarcopenia sarcopenia age related diseases EQUITY Funding $50,000 Initiated 09.10.2023 Dr. John Lewis Chief Science Officer Eric Garcia Chief Operating Officer Matthew Scholz CEO & Co-founder Stephen Hilbert Chief Business Officer AT A GLANCE Early-stage preclinical discovery : Area Genetic medicines : Status Ongoing : Patent Status PROJECT LINKS View g … enetic medicines : Status Ongoing : Patent Status PROJECT LINKS View governance proposal View on-chain vote Funding $50,000 Initiated 09.10.2023 Dr. John Lewis Chief Science Officer Eric Garcia Chief Operating Officer Matthew Scholz CEO & Co-founder Stephen Hilbert Chief Business Officer AT A GLANCE Early-stage preclinical discovery : Area Genetic medicines : Status Ongoing : Patent Status PROJECT LINKS View governance proposal View on-chain vote Oisín Biotechnologies is … rials, Oisín plans to initiate GLP toxicology studies in late 2024, file an IND application in 2025, and launch phase 1 clinical trials in 2026. With a focus on regulatory approval, Oisín is poised to bring their innovative therapies to market within the next five years. SAFE Funding Required Funding: $5M Duration: Ongoing VitaDAO Board Evaluation Writeup Oisín Biotechnologies presents a strong position in the biotech industry with its innovative Fusogenix Proteo-Lipid Vehi
Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics March 12, 2025 | 6 min read Twitter LinkedIn Facebook Email Print This investment will help build a 103,000-square-foot R&D … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Oisín Biotechnologies Included in MIT Technology Review’s “TR10” List of Top 10 Breakthrough Technologies of 2020 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Oisín Biotechnologies Included in MIT Technology Review’s “TR10” List of Top 10 Breakthrough Technologies of 2020 February 26, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Feb. 26, 2020 12:08 UTC Oisín Biotechnologies Included in MIT Technology Review’s “TR10” List of Top 10 Breakthrough Technologi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Oisín Biotechnologies Raises Seed Funding to Advance Therapies for Age-Related Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioForest Oisín Biotechnologies Raises Seed Funding to Advance Therapies for Age-Related Diseases May 27, 2021 | 3 min read Twitter LinkedIn Facebook Email Print -- Investment brings total funding to $9.5 million -- Financing will support preclinical development of its platform and investigational therapy for kidney and … first clinical trial. About Althea Group Althea Group is an early stage venture fund with a track record of significant value creation. Althea’s unique global network spanning finance, academia, public corporations, and start-up operators, enables it to identify, invest in, and grow mission-driven, tenacious founding teams focused on building great products and companies. For more information email us at [email protected] or visit us at https://www.linkedin.com/company/alt … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
VDP-120 [Assessment]: Oisín Biotechnologies - Genetic Medicines for Health and Longevity - Proposals - Governance Forum | VitaDAO Governance Forum | VitaDAO VDP-120 [Assessment]: Oisín Biotechnologies - Genetic Medicines for Health and Longevity Proposals gweisha September 1, 2023, 1:12pm 1 One-liner: Oisín Biotechnologies is a multi-asset longevity biotech company pioneering genetic medicines to combat sarcopenia and other age-related diseases to promote healthier, longer lives. Longevity Dealflow WG team Senior Reviewers: 2 scientists, 1 pharma professional, 1 VC, 1 biotech entrepreneur Shep … corporation and has raised $11.2M. Notable investors include SENS Foundation, M Fund, Althea, Kizoo, Healthspan Ventures, and several prominent angel investors in the longevity community. They have already identified a putative lead investor for their subsequent Series A. Team Leadership Matthew Scholz - CEO & Co-founder 20+ years experience starting and running biotech companies. Founder of Immusoft, creator of the first engineered B cell therapy allowed to enter human t … controls. Traction: Oisin has already sold a license option of its follistatin application to a large pharmaceutical company providing further validation of the approach and existing preclinical data. If successful in human trials and subsequent regulatory approval, this therapy could become available within the next five years. Market Opportunity: With sarcopenia-related healthcare costs in the U.S. already at $18.5B in 2020 and rising, Oisín’s follistatin-based therapy, co … mouse puddles? michele.gallia September 5, 2023, 9:31pm 3 This is an excellent proposal - Lots of data - especially the fact that they have data in humans, already. Clear IP Strategy, great commercial potential and well thought-through risks my only concern is that the total amount requested is such that VitaDAO will get a very small share of it, and as a general rule I think it is better to be a big fish in a small pond than a small fish in a big pond Does the company have … ession restricted to muscle cells? Or is it everywhere? Same with the senolytic application. Is that CMV too? gweisha: Our adipocyte killing data was in human tissue explants. Ok, thought you were getting those results in the mouse, which is a genetic fat loss system. The human explants were not as graphic. Is the 20% loss due to poor delivery, l
Oisín Biotechnologies Publishes Preclinical Data on Muscle-Building Gene Therapy in Cell Products Data Feature Plans Request Demo Sign Up for Free Oisín Biotechnologies Publishes Preclinical Data on Muscle-Building Gene Therapy in Cell 14 September 2024 Oisín Biotechnologies, a biotechnology company focused on combating age-related diseases , has released preclinical data from its follistatin (FST) gene therapy program. The study, published in the journal Cell, is titled "Safe and Effective Delivery of DNA and RNA Using Proteolipid Vehicles." This research is a collaborative effort involving s
Oisín Biotechnologies Announces Publication of Preclinical Data from its Muscle Building Gene Therapy Program in Cell - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Oisín Biotechnologies Announces Publication of Preclinical Data from its Muscle Building Gene Therapy Program in Cell September 11, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Data show that follistatin gene therapy using proteolipid vehicles increases muscle mass, body weight, and grip streng … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Oisín Biotechnologies 0 Skip to Content Home Team Contact Open Menu Close Menu Home Team Contact Open Menu Close Menu Home Team Contact Genetic Medicines for Health and Longevity Oisín has a robust pipeline targeting multiple drivers of age-related conditions. We have programs that target frailty by stimulating muscle growth, selectively kill fat cells, and remove senescent cells. Our therapies leverage a new, non-viral delivery technology known as Fusogenix™ Proteo-Lipid Vehicle (PLV). This technology enables extensive extrahepatic biodistribution for both DNA and RNA payloads and permits saf
Matthew Scholz's email - Chief Executive Officer | Oisin Biotechnologies | FinalScout Home Pricing API Support Contact us Extension Sign in Free Trial MS Matthew Scholz Founder and Chief Executive Officer at Oisín Biotechnologies Request removal Email: ****[email protected] LinkedIn: Matthew Scholz Location: Seattle, Washington, United States Current employer: Oisin Biotechnologies Current title: Chief Executive Officer Last updated: 02/05/2024 04:21 AM Get valid emails for Matthew and 500M other professionals 20 free emails each month. No credit card required. 500M Business Profiles 20M Company
Matthew Scholz - Immusoft Home About Our Mission Leadership Board of Directors Scientific Advisory Board Science Our Approach The B Cell Advantage Research Pipeline Investors & Media Press Releases News Articles Publications & Presentations Contact Careers Home About Our Mission Leadership Board of Directors Scientific Advisory Board Science Our Approach The B Cell Advantage Research Pipeline Investors & Media Press Releases News Articles Publications & Presentations Contact Careers Team Leadership Board Of Directors Matthew Scholz Founder, Board Member Matthew Scholz is Immu … former President of Caltech, David Baltimore, could be modified for a practical application: programming resting B cells to secrete therapeutic proteins. He negotiated an exclusive license to the system, then developed and patented a way to improve its efficiency to the point it was clinically viable. This modified system remains the core of Immusoft’s technology platform today. After Immusoft, Matthew co-founded Oisín Biotechnologies. He serves as Oisín’s Chief Executive Off … Washington. He served for several years as a mentor to recipients of the Thiel Fellowship, a program that awarded grants to some of the world’s brightest scientific minds under age 20. Home About Our Mission Leadership Board of Directors Scientific Advisory Board Science Our Approach The B Cell Advantage Research Pipeline Investors & Media Press Releases News Articles Publications & Presentations Contact Careers © IMMUSOFT 2026 | 454 N 34th St., Seattle, WA 981
Team — Oisín Biotechnologies 0 Skip to Content Home Team Contact Open Menu Close Menu Home Team Contact Open Menu Close Menu Home Team Contact Executive Team Matthew Scholz Chief Executive Officer John Lewis, Ph.D. Chief Science Officer Eric Garcia Chief Operating Officer Stephen Hilbert Chief Business Officer Henry Garcia, Ph.D. Head of Aging R&D Alexandre Gingras, Ph.D. Head of Preclinical Manufacturing Board of Directors Matthew Scholz Chief Executive Officer Gary Hudson Chairman Danjuma Quarless, Ph.D David Gobel Oisín Biotechnologies 701 Fifth Avenue Suite 4200 Seattle, WA 98104
Oisín Biotechnologies Receives Methuselah Grant to Advance Fat Reduction Study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer O … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Oisín Biotechnologies Receives Methuselah Grant to Advance Fat Reduction Study December 18, 2024 | 2 min read Twitter LinkedIn Facebook Email Print SEATTLE--(BUSINESS WIRE)--Oisín Biotechnologies, a leading genetic medicines company developing therapies for age-related diseases, announced today that it ha … therapies for age-related diseases, announced today that it has been awarded a grant from Methuselah Foundation to complete its first efficacy study in pigs for its innovative fat reduction program. Oisín is leveraging the Fusogenix™ Proteo-Lipid Vehicle (PLV) technology to deliver a fat killing genetic payload directly to adipose tissue. This precise approach allows for targeted, localized ablation of fat deposits via direct injection. The company's prior tolerability study … Oisín’s work in the field of aging research. Fueling Growth and Innovation This grant from Methuselah Foundation supports a pivotal study and is a significant step on our path to the clinic. “We are pleased to support Oisín Biotechnologies as they pursue this groundbreaking study,” said David Gobel, Chairman of Methuselah Foundation. “Their innovative approach has the potential to redefine therapies for age-related diseases and unlock new ways to address some of the most pres … dation for their continued belief in our vision and for providing this generous grant,” said Matthew Scholz, CEO of Oisín Biotechnologies. “This funding comes at a pivotal moment as we prepare to advance our fat reduction program to the next stage of development. It not only sustains our momentum but also empowers us to make strides toward delive